Valentina Molteni

Summary

Affiliation: Genomics Institute of the Novartis Research Foundation
Country: USA

Publications

  1. ncbi The nuclear receptor LXR is a glucose sensor
    Nico Mitro
    Genomics Institute of the Novartis Research Foundation, 10675 John Hopkins Drive, San Diego, California 92121, USA
    Nature 445:219-23. 2007
  2. ncbi Identification of novel potent bicyclic peptide deformylase inhibitors
    Valentina Molteni
    Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 14:1477-81. 2004
  3. ncbi N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta
    Valentina Molteni
    Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, USA
    J Med Chem 50:4255-9. 2007
  4. ncbi Liver X receptor modulators: a review of recently patented compounds (2007 - 2009)
    Xiaolin Li
    Genomics Institute of the Novartis Research Foundation, Department of Medicinal Chemistry, San Diego, CA 92121, USA
    Expert Opin Ther Pat 20:535-62. 2010
  5. ncbi N-phenylphenylglycines as novel corticotropin releasing factor receptor antagonists
    Valentina Molteni
    Bristol-Myers Squibb Pharma Research Laboratories, 4570 Executive Drive, Suite 400, San Diego, California 92121, USA
    J Med Chem 47:2426-9. 2004
  6. ncbi Arylamidrazones as novel corticotropin releasing factor receptor antagonists
    Dean M Wilson
    J Med Chem 45:2123-6. 2002

Collaborators

Detail Information

Publications6

  1. ncbi The nuclear receptor LXR is a glucose sensor
    Nico Mitro
    Genomics Institute of the Novartis Research Foundation, 10675 John Hopkins Drive, San Diego, California 92121, USA
    Nature 445:219-23. 2007
    ..Our results identify LXR as a transcriptional switch that integrates hepatic glucose metabolism and fatty acid synthesis...
  2. ncbi Identification of novel potent bicyclic peptide deformylase inhibitors
    Valentina Molteni
    Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 14:1477-81. 2004
    ..Many of the compounds synthesized proved to be excellent PDF-Ni inhibitors and some showed increased antibacterial activity in selected strains...
  3. ncbi N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta
    Valentina Molteni
    Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, USA
    J Med Chem 50:4255-9. 2007
    ..Our results indicate that it is possible to achieve significant LXRbeta selectivity in a small molecule while maintaining functional LXR activity...
  4. ncbi Liver X receptor modulators: a review of recently patented compounds (2007 - 2009)
    Xiaolin Li
    Genomics Institute of the Novartis Research Foundation, Department of Medicinal Chemistry, San Diego, CA 92121, USA
    Expert Opin Ther Pat 20:535-62. 2010
    ..Take home message: The future application of LXR agonists depends upon the discovery of LXR agents without lipogenic effects. Limiting activation of LXRalpha is a popular strategy...
  5. ncbi N-phenylphenylglycines as novel corticotropin releasing factor receptor antagonists
    Valentina Molteni
    Bristol-Myers Squibb Pharma Research Laboratories, 4570 Executive Drive, Suite 400, San Diego, California 92121, USA
    J Med Chem 47:2426-9. 2004
    ..This structural class represents the first example of a non-peptide CRF(1) antagonist with a stereochemically distinct receptor binding affinity...
  6. ncbi Arylamidrazones as novel corticotropin releasing factor receptor antagonists
    Dean M Wilson
    J Med Chem 45:2123-6. 2002
    ..With appropriate left-hand-side modifications, this potency loss could be recovered...